Ibrutinib Receives Orphan Drug and Breakthrough Therapy Designation for cGVHD

Article

The drug received breakthrough therapy and orphan drug designation as a monotherapy for the treatment of chronic graft-versus-host-disease.

On June 29, 2016 FDA granted Imbruvica (ibrutinib) Breakthrough Therapy designation and Orphan Drug designation as a monotherapy for the treatment of patients with chronic graft-versus-host-disease (cGVHD) after failure or one more lines of systematic therapy. This is the fourth Breakthrough Therapy designation for the drug, Reuters noted in a brief.

Imbruvica works by blocking Bruton’s tyrosine kinase (BTK). The BTK protein transmits signals that tell B cells to mature and multiply. Imbruvica targets and blocks BTK, inhibiting cancerous B cells to survive and spread. Imbruvica is currently being studied alone in combination with other treatments in several blood and solid tumor cancers and other serious illnesses.

Imbruvica is co-developed and commercialized by Pharmacyclics, an AbbVie company, and Janssen Biotech. AbbVie acquired Pharmacyclics and Imbruvica in March 2015 for $261.25 per share. AbbVie also acquired Stemcentrx in late April 2016. Both acquisitions are a strategic move for the company, which is looking to expand its oncology pipeline.

Source: AbbVieJanssen Pharmaceuticals

 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Related Content
© 2025 MJH Life Sciences

All rights reserved.